Press Release

Granules India's FY15 Revenue increases 18% to Rs. 1,293 Cr.; Net Profit rises 21% to Rs. 91 Cr

Hyderabad, April 27, 2015: Granules India Ltd., a fast growing pharmaceutical manufacturing company, announced financial results for its financial year ended March 31, 2015. Granules consolidated net sales increased 18% to Rs. 1,293 Cr. while consolidated net profit increased 21% to Rs. 91 Cr.

Financial Highlights for the Fiscal Year ended March 31, 2015

- Net Revenue: Rs. 1,293 Cr., an increase of 18% compared to Rs. 1,096 Cr. in FY14
- EBITDA: Rs. 213 Cr., an increase of 31% compared to Rs. 163 Cr. in FY14
- PBT: Rs. 128 Cr., an increase of 14% compared to Rs. 112 Cr. in FY14
- Net Profit: Rs. 91 Cr., an increase of 21% compared to Rs. 75 Cr. in FY14

The Company has recorded sales of Rs. 355 Cr. for Q4FY15, 12% higher than the corresponding quarter in FY14. The EBITDA and PAT were Rs. 52 Cr. and Rs. 22 Cr. respectively.

The Company's standalone sales during the year were Rs.1, 213 Cr., an increase of 21% from previous year. EBITDA and PAT increased by 28% and 18% to Rs. 213 Cr. and Rs. 95 Cr. compare to last financial year. On a full year standalone basis, Finished Dosages continue to be the largest contributor to the business and constituted 38% of sales. PFI and API segment has contribution of 28% and 34% of sales respectively. Sales to the regulated markets increased to 69% against 65% compare to last financial year.

The Company's Board of Directors has declared a dividend of 50 paise /share representing 50% of Paid up Capital for the financial year 2014-15

"The past year was exciting for Granules because we bolstered new growth opportunities while reinforcing our foundation. Our push to diversify into higher value products was boosted by the inauguration of a world-class API facility in Vizag with our partner, Ajinimoto OmniChem. We also commercialized the sale of Abacavir, an anti-retroviral drug, which was developed by our internal R&D Team. In addition, our team was successful in turning around Auctus during the fourth quarter and we anticipate operations will continue to improve.

While our new opportunities are exciting, the team remains focused on our foundation. We maintained our standard of being U.S, FDA compliant with successful inspections at our Bonthapally and Gagillapur facilities. In addition, revenue and profit margins continue to improve within the core business. We look forward to solidifying our fundamentals while adding more products to our portfolio in the new fiscal year" said Krishna Prasad, Chairman & Managing Director of Granules India.

About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Granules has the largest PFI facility in the world with an industry leading 6 ton batch size. The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

Granules has strengthened its advantages through its Operational Excellence (OE) department which looks at every step of the manufacturing process in order to gain efficiencies and has also implemented systems that have standardized quality and reduced variation. The Company's OE program is regularly cited by MNCs as a "best in class" program and is the comparative advantage that lets Granules provide world-class quality products at a lower cost than its competitors. The adoption of the OE philosophy by Granules has earned it several recognitions including The Economic Times Manufacturing Excellence Awards 2011.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

Contacts:
Gayatri Ganesh
Genesis Burson-Marsteller
+91 9703700884
gayatri.ganesh@bm.com

Appendix